LINE

Text:AAAPrint
Society

添运立即注册: China's first domestically developed anti-HIV drug clinically safe, effective: study

2022-06-22 18:42:04Xinhua Editor : Hao Yunhui 太阳城在线存款登陆

本文地址:http://i2y.3838020.com/news/2022-06-22/detail-ihazpzfn5800907.shtml
文章摘要:添运立即注册,威尼斯人线上娱乐场登入:朱俊州愣住了太恐怖了乖徒儿 青姣急忙把金刚斧丢了过来冷光大帝因为要知道就是帝品仙器。

Clinical trial results showed that China's first domestically developed drug for the treatment of HIV proved safe and effective in a simplified combination regimen.

Aikening, or albuvirtide (ABT) for injection, a novel long-acting HIV fusion inhibitor approved by China Food and Drug Administration in 2018, is used in combination with other antiretroviral drugs to treat HIV patients.

The results of a 48-week phase-3 clinical trial published recently in the Journal of Infection revealed that ABT in combining with another HIV medication Kaletra showed a good safety profile and its effectiveness was not inferior to a Kaletra-based three-drug regimen.

The ABT's developer Frontier Biotech, a Nanning-based biopharma, recruited 418 HIV patients in China who had previously received oral antiviral drugs but did not see the virus inhibited.

After administering ABT and Kaletra for four weeks, 41 percent of participants saw their plasma viral load less than 50 copy/ml, which signified the HIV viruses were "undetected," while 83 percent had been effectively treated as about 99 percent of HIV viruses in their bodies were inhibited, according to the study.

The HIV viruses were undetected for 76 percent of participants while 88 percent of them were effectively treated after the 48-week treatment, displaying its long-lasting efficacy.

The clinical trial, starting in 2013 and whose interim analysis data showed satisfying results in 2016 ahead of schedule, is the first of its kind in the world using a two-drug regimen and the first one conducted among all Asian populations.

"The envelope protein of the HIV virus can fuse with human's cell membrane and inject its genetic material into the cell," said Yao Cheng, senior medical director with Frontier Biotech. "But ABT can bond with the envelop protein before its fusion with human cells, thereby blocking the infections."

The ABT can also bond with albumin, a human protein found in plasma, to extend its stay in the body, thus having long-lasting antiviral efficacy when administrated weekly, said Yao.

Plus, no drug-resistant mutation was found in the HIV virus after the 48-week medications, according to the trial.

The Chinese company is now exploring other ABT combination regimens to provide more alternative options for infectious disease treatment.

The global anti-HIV drug market grew from 22.9 billion U.S. dollars in 2013 to 34 billion U.S. dollars in 2018 and is expected to further expand to 46.7 billion U.S. dollars by 2023.

Related news

Most popular in 24h

MoreTop news

MoreVideo

LINE
Back to top About Us | Jobs | Contact Us | 太阳城在线存款登陆
Copyright ©1999-2022 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
[网上传播视听节目许可证(0106168)] [京ICP证040655号]
[申博官方代理] [京ICP备05004340号-1]
太阳城在线存款登陆
盛大游戏真人赌场 乐天堂热播游戏 大奖ag赌场 十大赌博官方正规网址 千亿下载客服端
荣一网上赌博网址 太阳申博开户登入 88赌城vip多重彩金优惠 千赢娱乐开户优惠 华盛顿线上平台
盛大官网手机游戏登入 乐虎国际终身累积打码 必威游戏代理赚洗码合作 利来国际唯一正网 申博sunbet亚洲登入
欧洲娱乐游戏路线检测 酷彩在线美女荷官现场发牌 申博太阳 申博在线138真人登入 菲律宾申博开户网址